Wilson Sonsini Goodrich & Rosati advised Vida Ventures on IP matters related to the transaction. Third Arc Bio Inc., a biotech company, announced a $165 million...
Third Arc Bio’s $165 Million Series A Financing Round
Avalyn Pharma’s $175 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
Vigil Neuroscience’s $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...